Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Accesswire October 29, 2024

Terry Lynch Joins BioNxt as Capital Markets Advisor

Accesswire October 7, 2024

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

Accesswire September 26, 2024

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Accesswire September 9, 2024

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Accesswire August 15, 2024

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

Accesswire July 17, 2024

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Accesswire July 9, 2024

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

Accesswire June 19, 2024

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile June 13, 2024

Bionxt Solutions Announces Odf Cladribine Update and Financing

Accesswire April 25, 2024

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

Accesswire March 18, 2024

BioNxt Reports Successful Results From ODF Cladribine PK Study

Accesswire March 13, 2024

BioNxt completes study on its oral MS treatment

Jonathon Brown March 4, 2024

BioNxt Reports Completion of ODF Cladribine PK Study

Accesswire March 4, 2024

BioNxt Solutions Finalizes Agreement

Accesswire February 16, 2024

BioNxt reveals results from multiple sclerosis treatment study

Jocelyn Aspa February 7, 2024

BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

Accesswire February 7, 2024

BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Accesswire January 29, 2024

BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing

Accesswire December 21, 2023

BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products

Accesswire December 12, 2023